NASDAQ
Allogene Therapeutics, Inc. (ALLO) has a price/fcf ratio of -2.02x as of Monday, May 25, 2026. This represents a 55.07% increase compared to its 12-month average of -4.50x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.